PODIS, why acquisition by BESSE MEDICAL is so exciting. EYE NEWS TV

(1:57)

Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Advanced NSCLC

(1:10)

Besse Medical at the 23rd Annual PAHCOM Conference

(27)

Besse Medical @ the PAHCOM Conference

(1:23)

How to maximize your customer experience with Eric Besse | Besse Medical

(42:18)

ADCs for the treatment of NSCLC

(2:50)

Dr. Besse Discusses MARIPOSA Analysis on Mechanisms of Acquired Resistance

(4:7)

OSE Immunotherapeutics - Key opinion leader webinar with Dr Stephen Liu and Professor Benjamin Besse

(45:23)

Besse 6/19/12

(3:4)

Dr. Besse on Combination of Necitumumab and Abemaciclib in NSCLC

(1:29)

Free software leads to DOJ fine for drug distributor

(47)

Besse

(5:21)

Optimal duration of immunotherapy administration for patients with NSCLC

(2:28)

EGFR-Positive NSCLC: Treatment at Progression

(6:41)

Dr. Benjamin Besse on First vs Next Generation TKIs for NSCLC With Driver Mutations

(4:56)

Efficacy of a new treatment in small cell lung cancer

(2:)

Management of toxicities - BENJAMIN BESSE

(35:23)

Combining ADCs with other treatment modalities in NSCLC

(1:47)

Besse Herianti_18200100074

(10:21)

Besse Herianti_1820010074

(13:27)